Maximum quantity allowed is 999
Please select the quantity
CAS RN: 132539-06-1 | Product Number: O0393
Olanzapine

Purity: >98.0%(GC)(T)
Synonyms:
- 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine
Product Documents:
* Please contact our distributor of SEJIN CI Co., Ltd.
if you would like to purchase TCI products. The above prices do not include freight cost, customs charge and other charges to the destination. SEJIN CI Co., Ltd. (Phone: 02-2655-2480 / email:
sales@sejinci.co.kr)
* The storage conditions are subject to change without notice.
* The storage conditions are subject to change without notice.
Product Number | O0393 |
Purity / Analysis Method | >98.0%(GC)(T) |
Molecular Formula / Molecular Weight | C__1__7H__2__0N__4S = 312.44 |
Physical State (20 deg.C) | Solid |
Storage Temperature | Refrigerated (0-10°C) |
Condition to Avoid | Heat Sensitive |
Packaging and Container | 1G-Glass Bottle with Plastic Insert (View image) |
CAS RN | 132539-06-1 |
Reaxys Registry Number | 7655141 |
PubChem Substance ID | 160871343 |
Merck Index (14) | 6822 |
MDL Number | MFCD00866702 |
Specifications
Appearance | Light yellow to Amber to Dark green powder to crystal |
Purity(GC) | min. 98.0 % |
Purity(Nonaqueous Titration) | min. 98.0 % |
Properties (reference)
Melting Point | 194 °C(dec.) |
Solubility in water | Insoluble |
GHS
Pictogram |
![]() |
Signal Word | Danger |
Hazard Statements | H301 : Toxic if swallowed. H315 : Causes skin irritation. H319 : Causes serious eye irritation. H413 : May cause long lasting harmful effects to aquatic life. |
Precautionary Statements | P501 : Dispose of contents/ container to an approved waste disposal plant. P273 : Avoid release to the environment. P270 : Do not eat, drink or smoke when using this product. P264 : Wash skin thoroughly after handling. P280 : Wear protective gloves/ eye protection/ face protection. P302 + P352 : IF ON SKIN: Wash with plenty of water. P337 + P313 : If eye irritation persists: Get medical advice/ attention. P305 + P351 + P338 : IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. P362 + P364 : Take off contaminated clothing and wash it before reuse. P332 + P313 : If skin irritation occurs: Get medical advice/ attention. P301 + P310 + P330 : IF SWALLOWED: Immediately call a POISON CENTER/doctor. Rinse mouth. P405 : Store locked up. |
Related Laws:
RTECS# | XJ9007750 |
Transport Information:
UN Number | UN2811 |
Class | 6.1 |
Packing Group | III |
H.S.code* | 2934.99-000 |
Application
Bone research
References
- Atypical antipsychotics induce human osteoblasts apoptosis via Wnt/β-catenin signaling
- Effects of Olanzapine on Bone Mineral Density, Glucose, and Lipid Metabolism in Schizophrenia Patients
Application
Olanzapine: A Multi-Acting Receptor Targeted Antipsychotic (MARTA)
Olanzapine is known as a multi-acting receptor targeted antipsychotic (MARTA), such as clozapine [C2547] and quetiapine [Q0092]. Olanzapine has greater affinity for serotonin 5-HT2A and dopamine D2 receptors. Furthermore, olanzapine has various affinities for multiple receptors, including serotonin 5-HT2C, 5-HT6 receptors, dopamine D1-4, histamine H1, and adrenergic α1 receptors. In addition, olanzapine has moderate affinity binding for serotonin 5HT3 and muscarinic M1-5. While, olanzapine binds weakly to GABAA, benzodiazepine (BZD), and β-adrenergic receptors. The precise mechanism of action is unknown, but olanzapine is used as a thienobenzodiazepine atypical antipsychotic.
Recently, it is reported that the use of olanzapine combined with a 5-HT3 receptor antagonist, a neurokinin1 (NK1) receptor antagonist and dexamethasone [D1961] has improved the control of acute chemotherapy-induced nausea and vomiting. (The product is for research purpose only.)
Recently, it is reported that the use of olanzapine combined with a 5-HT3 receptor antagonist, a neurokinin1 (NK1) receptor antagonist and dexamethasone [D1961] has improved the control of acute chemotherapy-induced nausea and vomiting. (The product is for research purpose only.)
References
- Radioreceptor binding profile of the atypical antipsychotic olanzapine
- Binding of antipsychotic drugs to human brain receptors - focus on newer generation compounds
- 5-HT2A and D2 receptor blockade increases cortical DA release via 5-HT1A receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release
- Olanzapine: An updated review of its use in the management of schizophrenia
- Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhea
- Pharmacokinetics and tissue distribution of olanzapine in rats
- Development of a stability-indicating HPLC method for simultaneous determination of olanzapine and fluoxetine in combined dosage forms
PubMed Literature
Articles/Brochures
TCIMAIL
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.